{
  "id": 1753671,
  "title": "BioCardia CEO Peter Altman buys $5,022 in company stock",
  "url": "https://urgent.news/2026/08/18/biocardia-ceo-peter-altman-buys-5-022-in-company-stock",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-08-18T16:45:53.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/insider-trading-news/biocardia-ceo-peter-altman-buys-5022-in-company-stock-93CH-4865789"
  },
  "original_language": "en",
  "account": "BioCardia CEO and President Peter Altman bolstered his stake in the company by purchasing 5,400 shares on August 17, 2026, for a total of $5,022. The acquisition was made at prices between $0.92 and $0.97 per share, with a weighted average price of $0.93 per share. Despite a 50% decline over the past year, the stock is trading close to its 52-week low of $0.75. According to InvestingPro analysis, BioCardia Inc. appears undervalued at the moment, with a Fair Value pointing to potential upside.\n\nFollowing the purchase, Altman directly owns 381,115 shares of BioCardia common stock, representing 13.14% of the company's outstanding shares. Investors can obtain a more comprehensive view of BioCardia's financial health by accessing the Pro Research Report, which covers the company alongside 1,400+ other US equities.\n\nRecently, BioCardia reported a smaller-than-expected loss for the second quarter of 2026, with an adjusted earnings per share (EPS) loss of $0.13, outperforming the $0.18 loss expected by analysts—a 27.78% surprise. This positive earnings news comes alongside significant regulatory progress, with Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) approving a Shonin submission for BioCardia's CardiAMP cell therapy. Furthermore, the U.S. Food and Drug Administration (FDA) staff suggested that the CardiAMP Heart Failure II trial could support pre-market approval, bolstering the company's regulatory outlook in the United States.\n\nBioCardia holds a cash reserve of $5.4 million at the end of the quarter, ensuring financial resilience into 2027. The company's net cash used in operations was $1.7 million for the quarter, slightly higher than the $1.6 million used in the same period from the previous year. Operating cash use for the first half of the year was $3.4 million, marginally up from the prior-year period. These developments underscore BioCardia's dedication to advancing its cell therapy and delivery platform.",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}